New Protocol: Atezolizumab with Carbo-Pem-Bev for Pleural Mesothelioma

Randomized, open-label, phase 3 trial (BEAT-meso)

Unresectable, untreated pleural mesothelioma patients

Atezolizumab + cisplatin + pemetrexed + bevacizumab (Atezo-CPB) vs. cisplatin + pemetrexed + bevacizumab (CPB)

ORR: 55% vs. 49% (Atezo-CPB vs. CPB)

DCR @6mos: 67% vs. 58%

mPFS: 9.2 mos vs. 7.6 mos (HR: 0.72 [0.59–0.89])

mOS: 20.5 mos vs. 18.1 mos (HR: 0.84 [0.66–1.06])

HR for mOS among non-epithelioid: 0.50 [032.-0.78]

AE-related discontinuation: 9.8% vs. 10.6% (Atezo-CPB vs. CPB)

AE-related death: 3.5% vs. 0.5%

Most common grade ≥3 AEs: neutropenia (16% vs. 13%), anemia (10% vs. 8%), hypertension (13% vs. 13%)

Felip E,Popat S,Dafni U A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial

Reviewed by Ulas D. Bayraktar, MD on May 4, 2025